Fig. 2.

MADRS response in patient subgroups. Differences for vilazodone versus placebo in MADRS response were significant in each patient subgroup tested, with the exception of patients with an episode duration >12 months. (a) Catagorized by demographics and baseline symptom severity. (b) Categorized by MDD history. **P<0.01, ***P<0.001 versus placebo. CI, confidence interval; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; mo, months; n, number of patients with an available postbaseline MADRS total score; NNT, number needed to treat; y, years.